JP2020534362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534362A5 JP2020534362A5 JP2020537297A JP2020537297A JP2020534362A5 JP 2020534362 A5 JP2020534362 A5 JP 2020534362A5 JP 2020537297 A JP2020537297 A JP 2020537297A JP 2020537297 A JP2020537297 A JP 2020537297A JP 2020534362 A5 JP2020534362 A5 JP 2020534362A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cbd
- effective amount
- reduced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 22
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 22
- 229950011318 cannabidiol Drugs 0.000 claims 21
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 21
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 21
- 206010010904 Convulsion Diseases 0.000 claims 7
- 229960001403 clobazam Drugs 0.000 claims 2
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- BMPDWHIDQYTSHX-AWEZNQCLSA-N (S)-MHD Chemical compound C1[C@H](O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-AWEZNQCLSA-N 0.000 claims 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims 1
- 208000034308 Grand mal convulsion Diseases 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- 208000032140 Sleepiness Diseases 0.000 claims 1
- 206010041349 Somnolence Diseases 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- -1 balproart Chemical compound 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960004028 eslicarbazepine Drugs 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 229960002623 lacosamide Drugs 0.000 claims 1
- VPPJLAIAVCUEMN-GFCCVEGCSA-N lacosamide Chemical compound COC[C@@H](NC(C)=O)C(=O)NCC1=CC=CC=C1 VPPJLAIAVCUEMN-GFCCVEGCSA-N 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 229960004002 levetiracetam Drugs 0.000 claims 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims 1
- 230000003908 liver function Effects 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 239000003368 psychostimulant agent Substances 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023145851A JP7650929B2 (ja) | 2017-09-19 | 2023-09-08 | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560446P | 2017-09-19 | 2017-09-19 | |
| US62/560,446 | 2017-09-19 | ||
| US201762593575P | 2017-12-01 | 2017-12-01 | |
| US62/593,575 | 2017-12-01 | ||
| US201862613160P | 2018-01-03 | 2018-01-03 | |
| US62/613,160 | 2018-01-03 | ||
| US201862652995P | 2018-04-05 | 2018-04-05 | |
| US62/652,995 | 2018-04-05 | ||
| US201862660198P | 2018-04-19 | 2018-04-19 | |
| US62/660,198 | 2018-04-19 | ||
| PCT/IB2018/057189 WO2019058261A1 (en) | 2017-09-19 | 2018-09-18 | TRANSDERMAL SYNTHETIC CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023145851A Division JP7650929B2 (ja) | 2017-09-19 | 2023-09-08 | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020534362A JP2020534362A (ja) | 2020-11-26 |
| JP2020534362A5 true JP2020534362A5 (https=) | 2021-10-28 |
Family
ID=63762572
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537297A Pending JP2020534362A (ja) | 2017-09-19 | 2018-09-18 | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール |
| JP2023145851A Active JP7650929B2 (ja) | 2017-09-19 | 2023-09-08 | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023145851A Active JP7650929B2 (ja) | 2017-09-19 | 2023-09-08 | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20190083388A1 (https=) |
| EP (1) | EP3684411A1 (https=) |
| JP (2) | JP2020534362A (https=) |
| KR (1) | KR20200055067A (https=) |
| AU (1) | AU2018337933A1 (https=) |
| BR (1) | BR112020004947A2 (https=) |
| CA (1) | CA3075719A1 (https=) |
| IL (2) | IL301910A (https=) |
| JO (1) | JOP20200045A1 (https=) |
| MX (2) | MX2020003004A (https=) |
| WO (1) | WO2019058261A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3733156A1 (de) * | 2019-05-02 | 2020-11-04 | Gábor Fóti | C.b.d.m therapie |
| BR112022004175A2 (pt) * | 2019-09-17 | 2022-05-31 | Zynerba Pharmaceuticals Inc | Tratamento de encefalopatia de syngap1 |
| AU2020358869A1 (en) | 2019-10-03 | 2022-04-14 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| EP4041209A4 (en) * | 2019-10-11 | 2024-01-24 | Pike Therapeutics, Inc. | TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| CA3155181A1 (en) | 2019-10-14 | 2021-04-22 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal delivery of cannabidiol |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| GB2597287A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| US20220047525A1 (en) * | 2020-08-17 | 2022-02-17 | Pike Therapeutics, Inc. | Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids |
| KR20230113622A (ko) * | 2020-12-03 | 2023-07-31 | 지네르바 파마슈티컬스, 인코포레이티드 | 난치성 발작의 치료를 위한 칸나비디올 |
| AU2022255944A1 (en) * | 2021-04-08 | 2023-10-12 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2760460C (en) | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
| PT2473475T (pt) * | 2009-08-31 | 2017-08-02 | Zynerba Pharmaceuticals Inc | Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas |
| GB2530001B (en) * | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) * | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
-
2018
- 2018-09-18 US US16/133,930 patent/US20190083388A1/en not_active Abandoned
- 2018-09-18 AU AU2018337933A patent/AU2018337933A1/en not_active Abandoned
- 2018-09-18 JP JP2020537297A patent/JP2020534362A/ja active Pending
- 2018-09-18 IL IL301910A patent/IL301910A/en unknown
- 2018-09-18 KR KR1020207011219A patent/KR20200055067A/ko not_active Ceased
- 2018-09-18 JO JOP/2020/0045A patent/JOP20200045A1/ar unknown
- 2018-09-18 WO PCT/IB2018/057189 patent/WO2019058261A1/en not_active Ceased
- 2018-09-18 EP EP18782520.3A patent/EP3684411A1/en not_active Ceased
- 2018-09-18 MX MX2020003004A patent/MX2020003004A/es unknown
- 2018-09-18 BR BR112020004947-6A patent/BR112020004947A2/pt unknown
- 2018-09-18 CA CA3075719A patent/CA3075719A1/en active Pending
-
2020
- 2020-02-20 IL IL272818A patent/IL272818A/en unknown
- 2020-03-18 MX MX2024002904A patent/MX2024002904A/es unknown
- 2020-08-18 US US16/996,082 patent/US20210030665A1/en not_active Abandoned
-
2023
- 2023-09-08 JP JP2023145851A patent/JP7650929B2/ja active Active
-
2024
- 2024-07-05 US US18/765,056 patent/US20250213465A1/en active Pending
-
2025
- 2025-01-28 US US19/039,288 patent/US20250302734A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534362A5 (https=) | ||
| US11793770B2 (en) | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy | |
| JP7650929B2 (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| JP2009529502A5 (https=) | ||
| JP2008523153A5 (https=) | ||
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| EP3390367B1 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
| KR20200090204A (ko) | 만성 염증성 및/또는 자가면역 질환의 예방 또는 치료에 사용하기 위한 비도플루디무스의 투여량 레지멘 | |
| JP2018506570A5 (https=) | ||
| RU2014111478A (ru) | Лечение с использованием ацетата эсликарбазепина или эсликарбазепина | |
| CN107510846A (zh) | 植物大麻素大麻二酚（cbd）与标准抗癫痫药物（saed）组合在治疗癫痫中的用途 | |
| JP2020514282A5 (https=) | ||
| FI4406594T3 (fi) | Kilpirauhashormonin analogeja | |
| JP2012533565A5 (https=) | ||
| MA33463B1 (fr) | Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique | |
| ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
| JP2010513229A5 (https=) | ||
| JP2020533296A5 (https=) | ||
| JP2012502915A5 (https=) | ||
| JP2015522652A5 (https=) | ||
| Hagino et al. | Tocilizumab for systemic juvenile idiopathic arthritis | |
| MA34130B1 (fr) | Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation | |
| JP2022508236A5 (https=) | ||
| CN111031814A (zh) | 用于偏头痛的预防和治疗的食品补充剂 | |
| JP2012097034A5 (https=) |